drugset
drugset / Trial / NCT00160316

Endometrial Safety Study of a 0.5 mg Estradiol and 2.5 mg Dydrogesterone Combination

NCT00160316 ↗

Phase 3 Completed 454 enrolled Solvay Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to demonstrate endometrial safety of continuous combined 0.5 mg estradiol and 2.5 mg dydrogesterone.

Timeline

Start
2005-04
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dydrogesterone Other / unclassified 2.5 mg Oral
Subject Estradiol Other / unclassified 0.5 mg Oral

Indications

No indication recorded.